EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of the Weight‐Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin‐Pemetrexed in EGFR ‐Mutated Non‐Small Cell Lung Cancer

Dongfen Yuan iD, Corey J Bishop iD, Jaydeep Mehta iD, Wangda Zhou iD, Lu Zhang iD, Jie Zhou iD, Raja Venkatasubramanian iD, Alex Yu iD, Trishala Agrawal, Sujay Shah, Mahadi Baig, Joshua M Bauml und 6 weitere

CPT: Pharmacometrics & Systems Pharmacology · 2026-06 · 15 (6)

DOI: 10.1002/psp4.70263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 21.05.2026. Verfasst von Dongfen Yuan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Spring House, Pennsylvania, USA. Hauptthemen laut MEDLINE: Carboplatin, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Johnson & Johnson, Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amivantamab, a bispecific antibody targeting epidermal growth factor and mesenchymal‐epithelial transition receptors, was initially approved under accelerated approval as a monotherapy for second‐line treatment of non‐small cell lung cancer (NSCLC) with exon 20 insertion mutations. Subsequently, amivantamab in combination with carboplatin‐pemetrexed demonstrated prolonged progression‐free survival compared to chemotherapy alone in the first‐line treatment of NSCLC with exon 20 insertion mutations and the second‐line treatment of NSCLC with exon 19 deletion or exon 21 L858R substitution mutations. To enable the combination with chemotherapy, the amivantamab regimen was changed from every 2 weeks (Q2W) to every 3 weeks (Q3W); both are weight‐tiered with a cutoff at 80 kg. Here we present the population pharmacokinetics (PK) and exposure‐response (E‐R) analysis supporting this dose regimen change. The population PK analysis demonstrated that the Q3W regimen achieved comparable trough concentrations as the approved Q2W regimen as well as between the two weight tiers. After accounting for confounding covariates, the E‐R relationship for PFS was flat in both indications. The safety profile of the Q3W regimen was generally manageable, despite trends of a positive E‐R relationship for adverse effects related to the mechanism of action. Besides weight, dose adjustment for other covariates was not warranted. These analyses supported the registration of the weight‐tiered Q3W regimen for amivantamab in combination with carboplatin‐pemetrexed in the new indications. This work demonstrates how the use of fit‐for‐purpose pharmacometrics analyses can support dose regimen changes without extensive dose selection clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarboplatinCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, BispecificHumansPemetrexedErbB ReceptorsMutationBody WeightFemaleMaleMiddle AgedAgedDose-Response Relationship, DrugAdult

Stichwörter der Autor:innen

amivantamabexposure matchingexposure‐response analysisnon‐small cell lung cancerpopulation pharmacokinetics analysis

Substanzen

CarboplatinPemetrexedErbB ReceptorsEGFR protein, humanAntibodies, Bispecific

Autor:innen und Institutionen

  • Johnson & Johnson, Spring House, Pennsylvania, USA.
  • Johnson & Johnson, Horsham, Pennsylvania, USA.
  • Johnson & Johnson, Raritan, New Jersey, USA.

ORCID-Profile: Dongfen Yuan, Corey J Bishop, Jaydeep Mehta, Wangda Zhou, Lu Zhang, Jie Zhou, Raja Venkatasubramanian, Alex Yu, Pamela L Clemens, Nahor Haddish-Berhane

Förderung

  • Johnson & Johnson
  • Johnson and Johnson

Zitieren

APA

Yuan, D., Bishop, C. J., Mehta, J., Zhou, W., Zhang, L., Zhou, J., Venkatasubramanian, R., Yu, A., Agrawal, T., Shah, S., Baig, M., Bauml, J. M., Kambuj, P., Ojeda, L. C., Clemens, P. L., Haddish-Berhane, N., Su, Y., & Samtani, M. (2026). Development of the Weight‐Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin‐Pemetrexed in EGFR ‐Mutated Non‐Small Cell Lung Cancer. CPT: Pharmacometrics & Systems Pharmacology, 15(6). https://doi.org/10.1002/psp4.70263

Vancouver

Yuan D, Bishop CJ, Mehta J, Zhou W, Zhang L, Zhou J, et al. Development of the Weight‐Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin‐Pemetrexed in EGFR ‐Mutated Non‐Small Cell Lung Cancer. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(6). doi:10.1002/psp4.70263

BibTeX
@article{Yuan2026,
  author = {Yuan, Dongfen and Bishop, Corey J and Mehta, Jaydeep and Zhou, Wangda and Zhang, Lu and Zhou, Jie and Venkatasubramanian, Raja and Yu, Alex and Agrawal, Trishala and Shah, Sujay and Baig, Mahadi and Bauml, Joshua M and Kambuj, Pritam and Ojeda, Lahila-Carina and Clemens, Pamela L and Haddish-Berhane, Nahor and Su, Yaming and Samtani, Mahesh},
  title = {Development of the Weight‐Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin‐Pemetrexed in EGFR ‐Mutated Non‐Small Cell Lung Cancer},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1002/psp4.70263}
}
Kostenlos starten →